EndoPredict can identify patients who may safely forgo chemotherapy or extended endocrine therapy

“…the data presented here demonstrate that the 12-gene assay identifies a population of women with node-positive disease who are at low enough risk for distant recurrence at the time of diagnosis that they may be adequately treated with only 5 years of adjuvant endocrine therapy.”

Filipits M, et al. Prediction of distant recurrence using Endopredict among women with ER+, HER2- node-positive and node-negative breast cancer treated with endocrine therapy only. Clin Cancer Res. 2019 May 7. [Epub ahead of print].

Learn More View Article

A high EPclin score can predict chemotherapy benefit in women with ER-positive, HER2-negative disease

“Our results furthermore suggest that some women with a low EPclin score, but clinically high-risk tumours received unnecessary chemotherapy. In addition, women with high EPclin scores who only received endocrine therapy alone would have been good candidates for adjuvant chemotherapy.”

Sestak I, et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019 Apr 30. [Epub ahead of print].

Learn More View Article

Greater prognostic value compared to first generation tests.

  • In all patients, EndoPredict was the best overall test in predicting distant recurrence (DR) in years 0-10 (C-index 0.753; LRx2=69.3)
  • EndoPredict identified the largest group of low-risk patients with 10 years DR below 10 percent in both node-negative and node-positive disease
  • EndoPredict was a better predictor for overall DR and for late-DR than Oncotype DX Recurrence Score

Sestak I, et al. Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer. JAMA Oncol. 2018 Apr; 4(4):545-553.

Learn More View Article

Provides classification more closely aligned with patient outcomes compared to Oncotype DX.®

“EPclin provided more prognostic information than RS [Oncotype DX Recurrence Score] partly because of its integration with node and tumor size information but also because of a superior molecular component able to predict late events better than (RS).”

Buus R, Sestak I, Kronenwett R, et al. Comparison of EndoPredict and EPclin with Oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst. 2016 Jul 10;108(11). pii: djw149. doi:10.1093/jnci/djw149. Print 2016 Nov.

Learn More View Article

More women classified as low risk.

“The EPclin score is able to predict favorable prognosis in a majority of patients that clinical guidelines would assign to intermediate or high risk. EPclin may reduce the indications for chemotherapy in ER-positive postmenopausal women with a limited number of clinical risk factors.”

Dubsky P, Filipits M, Jakesz R, et al. on behalf of Austrian Breast and Colorectal Cancer Study Group (ABCSG). EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer. Ann Oncol. 2013 Mar; 24(3):640-7.

Learn More View Article

EndoPredict demonstrates strong stratification of patients into one of two risk categories.

“The EPclin reliably identified a subgroup of patients who have an excellent long-term prognosis after 5 years of endocrine therapy.”

Dubsky P, Brase JC, Jakesz R, et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients. Br J Cancer 2013; 109(12):2959–64.

Learn More View Article

Stronger prognostic power than conventional risk factors.

“The multigene EndoPredict (EP) risk score provided additional prognostic information to the risk of distant recurrence of breast cancer patients, independent from clinicopathologic parameters. The EP score outperformed all conventional clinicopathologic risk factors.”

Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011; 17(18):6012–20.

Learn More View Article